{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:23Z","timestamp":1786996763267,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.semarthrit.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T23:25:18Z","timestamp":1616109918000},"page":"469-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial"],"prefix":"10.1016","volume":"51","author":[{"given":"Robert","family":"Spiera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian H.","family":"Unizony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Luder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Pavlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2021.03.006_bib0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2014.01.017","article-title":"The diagnosis and classification of giant cell arteritis","volume":"48-49","author":"Nesher","year":"2014","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.03.006_bib0002","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semarthrit.2017.04.001","article-title":"Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015","volume":"47","author":"Crowson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"9634","key":"10.1016\/j.semarthrit.2021.03.006_bib0003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.semarthrit.2021.03.006_bib0004","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.03.006_bib0005","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.03.006_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12877-019-1225-9","article-title":"Giant cell arteritis: is the clinical spectrum of the disease changing?","volume":"19","author":"Gonzalez-Gay","year":"2019","journal-title":"BMC Geriatr"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.03.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2019.06.006","article-title":"Early large vessel systemic vasculitis in adults","volume":"33","author":"Gonz\u00e1lez-Gay","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.03.006_bib0008","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.03.006_bib0009","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2016.11.006","article-title":"Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis","volume":"46","author":"Wilson","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.03.006_bib0010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","article-title":"Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis","volume":"46","author":"Broder","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2021.03.006_bib0011","first-page":"1","article-title":"Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK","author":"Gale","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.03.006_bib0012","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10031","key":"10.1016\/j.semarthrit.2021.03.006_bib0013","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.03.006_bib0014","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.03.006_bib0016","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/1756-185X.13723","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study","volume":"22","author":"Chino","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.03.006_bib0017","article-title":"Design of the tocilizumab in giant cell arteritis trial","volume":"2013","author":"Unizony","year":"2013","journal-title":"Int J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.03.006_bib0018","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.03.006_bib0019","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3899\/jrheum.141347","article-title":"Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study","volume":"42","author":"Kermani","year":"2015","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.03.006_bib0021","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 117(2)","key":"10.1016\/j.semarthrit.2021.03.006_bib0022","first-page":"57","article-title":"The different clinical patterns of giant cell arteritis","volume":"37","author":"de Boysson","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"10103","key":"10.1016\/j.semarthrit.2021.03.006_bib0023","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Gonzalez-Gay","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.03.006_bib0024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","article-title":"Large-vessel giant cell arteritis: a cohort study","volume":"54","author":"Muratore","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.03.006_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000162","article-title":"Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases","volume":"1","author":"Izumi","year":"2015","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.03.006_bib0027","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10067-014-2650-y","article-title":"Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy","volume":"35","author":"Mori","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.03.006_bib0028","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice","volume":"49","author":"Calderon-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:05:23Z","timestamp":1758733523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0049017221000366"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.03.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}